Skip to content

Hemab Therapeutics 控股

US · COAG #3007 按市值排名 上市于 2026
30.07 -2.45 -7.53%
实时 - 追踪5344个代码 - 心跳于424秒前 · 2026-10-16 19:30

最新新闻

  • Wedbush Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Maintains Target Price $42
    \u5e02\u573a\u8d44\u8baf · 2026/6/30
  • H.C. Wainwright Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $60
    \u5e02\u573a\u8d44\u8baf · 2026/8/12
  • Wedbush Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $64
    \u5e02\u573a\u8d44\u8baf · 2026/8/12
  • 评级变动
    Goldman Sachs Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $36
    \u5e02\u573a\u8d44\u8baf · 2026/5/26
  • 评级变动
    Hemab Therapeutics Holdings, Inc. (COAG) Receives a Buy From Wedbush
    TipRanks · 2026/6/30
  • 评级变动
    Jefferies Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Maintains Target Price $39
    \u5e02\u573a\u8d44\u8baf · 2026/6/9
  • 评级变动
    Wedbush Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $42
    \u5e02\u573a\u8d44\u8baf · 2026/5/26
  • Hemab Therapeutics Holdings, Inc. (COAG) Gets a Buy From Wedbush
    TipRanks · 2026/8/12
  • 评级变动
    Evercore Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $50
    \u5e02\u573a\u8d44\u8baf · 2026/5/26
  • 评级变动
    H.C. Wainwright Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Maintains Target Price $40
    \u5e02\u573a\u8d44\u8baf · 2026/6/27
  • 评级变动
    H.C. Wainwright Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $40
    \u5e02\u573a\u8d44\u8baf · 2026/6/17
  • 评级变动
    Jefferies Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $39
    \u5e02\u573a\u8d44\u8baf · 2026/5/26
  • 评级变动
    Jefferies Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $47
    \u5e02\u573a\u8d44\u8baf · 2026/7/14
  • Wedbush Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $55
    \u5e02\u573a\u8d44\u8baf · 2026/7/14
  • 评级变动
    H.C. Wainwright Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $52
    \u5e02\u573a\u8d44\u8baf · 2026/7/13

新闻标题为自动聚合内容,未经我们团队独立核实或编辑。

报价时间 2026-10-16 19:30:05 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

Hemab Therapeutics 控股 讨论区 0 条评论

发表评论